Regeneron Pharmaceuticals and Bayer HealthCare have commenced a new Phase III trial of their Eylea (aflibercept) injection for the treatment of diabetic macular edema (DME) in Russia, China, and other Asian countries.

Formulated as an iso-osmotic solution for intravitreal administration, recombinant fusion protein Eylea acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF), and inhibits the binding and activation of these cognate VEGF receptors.

The trial, named VEGF Trap-Eye In Vision Impairment Due to DME (VIVID EAST-DME), includes three treatment arms.

2mg of Eylea will be given to the first arm of patients every month and to the second arm of patients every two months, after an initial phase of five monthly injections.

" Eylea acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF), and inhibits the binding and activation of these cognate VEGF receptors."

The third comparator arm patients will be treated with macular laser photocoagulation, the currently available treatment for DME, according to the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Mean change in visual acuity from baseline to week 52, as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart, is the primary endpoint for the trial.

The study is expected to follow patients for a maximum of one year.

Previously, Eylea was approved for the treatment of wet age-related macular degeneration (AMD) in the US, Japan, Europe, Australia, and several other countries.

A separate Phase III trial of Eylea in DME, named VIVID-DME, will be conducted by Bayer HealthCare in Europe and Japan and a second study, named VISTA-DME will be conducted by Regeneron in the US.

In addition, Phase III trials are currently underway with Eylea in the treatment of myopic choroidal neovascularisation (mCNV) in Asia, and macular edema following branch retinal vein occlusion (BRVO) in the US, Canada and Japan.